Testing is done to check a wide range of gene tumor suppressor (anti- . gene) cancer ) in a tissue sample for diagnostic biopsy, potentially helping patients with rare cancers choose treatments.
Experiment Illumina performs more mutational searches than any other kit currently available, coming as the pharmaceutical industry struggles to develop precision cancer drugs for increasingly small populations of patients. determined by genetic profiling. This has created an unusually large demand for more sophisticated diagnostic tools.
Illumina’s comprehensive TruSight Oncology test kit looks for 517 cancer-related genes in nearly 30 solid tumor types, including mutations in TRK, an inherited factor in less than 1% of cancers, and Because of its rarity, it is often not tested despite the availability of the approved cancer drugs Vitrakvi from Bayer and Rozlytrek from Roche.
Illumina said: “Consolidating all the important biological features into one comprehensive test improves the odds of identifying treatment options that would otherwise require sequential genetic testing from multiple biopsy procedures.”.
Illumina said it is preparing to apply for US regulatory approval for the cancer test kit later this year.
at Blogtuan.info – Source: Soha.vn – Read the original article here
